Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Other Non Operating Income (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Other Non Operating Income for 6 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income rose 112.79% year-over-year to $1.5 million, compared with a TTM value of $14.4 million through Sep 2025, up 240.1%, and an annual FY2024 reading of $220000.0, down 91.66% over the prior year.
  • Other Non Operating Income was $1.5 million for Q3 2025 at Autolus Therapeutics, up from $133000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $12.6 million in Q4 2024 and bottomed at -$12.0 million in Q3 2024.
  • Average Other Non Operating Income over 4 years is $379733.3, with a median of $133000.0 recorded in 2025.
  • Peak annual rise in Other Non Operating Income hit 324.63% in 2024, while the deepest fall reached 593.65% in 2024.
  • Year by year, Other Non Operating Income stood at $6.3 million in 2022, then crashed by 52.46% to $3.0 million in 2023, then surged by 324.63% to $12.6 million in 2024, then plummeted by 87.81% to $1.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for AUTL at $1.5 million in Q3 2025, $133000.0 in Q2 2025, and $129000.0 in Q1 2025.